Plendil, 5 mg 30 pcs.

Plendyl – hypotensive, antianginal.

Blocks calcium channels, inhibits influx of calcium ions into the smooth muscle cells of arterial vessels, causes their dilation, reduces PPS, lowers BP, afterload on the heart, increases coronary blood flow, improves myocardial oxygen supply/consumption balance.

Pharmacokinetics

It is completely absorbed from the gastrointestinal tract. Systemic bioavailability is 15%. Binds to plasma proteins by 99%. Plasma concentration is directly proportional to the dose. It is metabolized in the liver. T_1/2 – 24 h. 70% is excreted in the urine (less than 0.5% of the dose unchanged), the rest in the feces.

Indications

Arterial hypertension, angina pectoris.

Pharmacological effect

Plendil – hypotensive, antianginal.

Blocks calcium channels, inhibits the flow of calcium ions into the smooth muscle cells of arterial vessels, causes their expansion, reduces peripheral vascular resistance, lowers blood pressure, afterload on the heart, increases coronary blood flow, improves the balance of oxygen supply/consumption to the myocardium.

Pharmacokinetics

Completely absorbed from the gastrointestinal tract. Systemic bioavailability – 15%. Binds to plasma proteins by 99%. Plasma concentration is directly proportional to dose. Metabolized in the liver. T1/2 – 24 hours. 70% is excreted in the urine (less than 0.5% of the dose unchanged), the rest is excreted in feces.

Active ingredient

Felodipin

Composition

Active ingredient:

felodipine 2.5 mg, 5 mg or 10 mg;

Excipients:

paraffin;

ethanol;

hydroxypropyl cellulose;

hydroxypropyl methyl cellulose;

iron oxide E 172;

lactose anhydrous;

MCC;

polyethylene glycol 6000;

polyoxyl 40 hydrogenated castor oil;

drank gallate;

sodium aluminum silicate;

sodium stearyl fumarate;

titanium dioxide E 171;

purified water

Pregnancy

Contraindicated during pregnancy and breastfeeding.

Contraindications

Hypersensitivity, decompensated heart failure, acute myocardial infarction, unstable angina, pregnancy, childhood.

Side Effects

Common (more than 1%): headache, hot flashes, peripheral edema.

Sometimes (0.1–1%): tachycardia, palpitations, feeling of fatigue, dizziness, paresthesia, nausea, rash, itching.

Rarely (0.01–0.1%): fainting, vomiting, arthralgia, myalgia, sexual dysfunction, impotence, urticaria.

Very rare (less than 0.01%): gingival hyperplasia, increased levels of liver enzymes, photosensitivity, pollakiuria, allergic reactions (fever, angioedema).

Interaction

Biotransformation inhibitors (cimetidine) increase plasma concentrations, stimulants (phenytoin, carbamazepine, barbiturates) decrease them.

Overdose

Symptoms: severe hypotension, bradycardia.

Treatment: transfer the patient to a supine position; symptomatic therapy – atropine (0.5-1 mg intravenously), alpha1-adrenergic agonists, glucose, saline solution or dextran infusion.

Storage conditions

At temperatures below 30 °C.

Shelf life

3 years

Manufacturer

AstraZeneca Pharmaceutical Co., Ltd., China